11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” Minoxidil sulfate significantly improved hair growth in mice.
Many patients in the rheumatology clinic adjusted or stopped their medications due to side effects.
1 citations
,
March 2016 in “Journal of The American Academy of Dermatology” More research needed to confirm finasteride as standard treatment for FFA.
October 2008 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” 5-alpha reductase inhibitors do not increase hip fracture risk.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
April 2018 in “Journal of Investigative Dermatology” A new peptide, FOL-005, may help treat excessive hair growth by reducing a hair growth promoter, FGF7.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
December 2025 in “PubMed” The minoxidil and finasteride foam remains stable and effective for 180 days at room temperature.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
20 citations
,
May 2023 in “Biological Trace Element Research” Daily intake of 0.5 or 5 mg cobalt ferrite nanoparticles can harm lungs through oxidative and inflammatory stress.
8 citations
,
July 1990 in “Archives of Dermatology” A woman had a skin reaction from a cough suppressant, dextromethorphan, which is a new cause of fixed-drug eruption.
30 citations
,
March 2007 in “Expert opinion on drug safety” Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
38 citations
,
March 2012 in “Zhongxiyi jiehe xuebao” Cuscuta reflexa Roxb. is a parasitic herb with many medicinal benefits.
The nutraceutical with rosemary may reduce inflammation in dog skin.
2 citations
,
February 2025 in “Free Radical Biology and Medicine” Blocking S100A8 can reduce chemotherapy-induced hair loss.
January 2021 in “Research Portal Denmark” Tofacitinib helped a man with alopecia totalis regrow all his hair.
October 2025 in “The American Journal of Gastroenterology” Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
18 citations
,
January 2022 in “Clinical Epidemiology” Higher doses of glucocorticoids increase the risk of blood clots in asthma patients.
11 citations
,
April 2020 in “Journal of Dermatological Treatment” Taking oral isotretinoin with creams worked better for treating a type of hair loss than creams alone.
April 2016 in “Journal of Investigative Dermatology” MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
35 citations
,
October 2017 in “Signal Transduction and Targeted Therapy” Fibromodulin treatment helps reduce scarring and improves wound healing by making it more like fetal healing.
2 citations
,
July 2025 in “RMD Open” IL-1 blockade is effective for treating SURF, and personalized treatment is needed.
October 2025 in “CRC Press eBooks”